Enhancement of fibrinolysis by a factor XA inhibitor edoxaban and combination with an inhibitor of activated thrombin-activatable fibrinolysis inhibitor in vitro

被引：0
|
作者：
Morishima, Y. [1 ]
Kamisato, C. [1 ]
Furugohri, T. [1 ]
机构：
[1] Daiichi Sankyo Co Ltd, Biol Res Labs, Tokyo, Japan
来源：
JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2015年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PO353-MON
引用
收藏
页码：390 / 390
页数：1
相关论文
共 50 条
  • [1] Thrombin-activatable fibrinolysis inhibitor
    Marx, PF
    CURRENT MEDICINAL CHEMISTRY, 2004, 11 (17) : 2335 - 2348
  • [2] Is there thrombin-activatable fibrinolysis inhibitor in saliva?
    Chopra, S.
    Friman, E.
    Krueger, C. W.
    Antovic, J. P.
    Naimi-Akbar, A.
    BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY, 2020, 58 (09): : E33 - E37
  • [3] Elucidation of the molecular mechanisms of two nanobodies that inhibit thrombin-activatable fibrinolysis inhibitor activation and activated thrombin-activatable fibrinolysis inhibitor activity
    Zhou, X.
    Weeks, S. D.
    Ameloot, P.
    Callewaert, N.
    Strelkov, S. V.
    Declerck, P. J.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2016, 14 (08) : 1629 - 1638
  • [4] Combined effect of a direct oral anticoagulant edoxaban and an inhibitor of activated thrombin-activatable fibrinolysis inhibitor on clot lysis
    Morishima, Yoshiyuki
    Kamisato, Chikako
    Honda, Yuko
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2020, 49 (01) : 94 - 99
  • [5] Combined effect of a direct oral anticoagulant edoxaban and an inhibitor of activated thrombin-activatable fibrinolysis inhibitor on clot lysis
    Yoshiyuki Morishima
    Chikako Kamisato
    Yuko Honda
    Journal of Thrombosis and Thrombolysis, 2020, 49 : 94 - 99
  • [6] The effects of hyperglycaemia on thrombin-activatable fibrinolysis inhibitor
    Verkleij, C. J. N.
    Nieuwdorp, M.
    Gerdes, V. E. A.
    Morgelin, M.
    Meijers, J. C. M.
    Marx, P. F.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 392 - 392
  • [7] Characterization of mouse thrombin-activatable fibrinolysis inhibitor
    Marx, PF
    Wagenaar, GTM
    Reijerkerk, A
    Tiekstra, MJ
    van Rossum, AGSH
    Gebbink, MFBG
    Meijers, JCM
    THROMBOSIS AND HAEMOSTASIS, 2000, 83 (02) : 297 - 303
  • [8] Thrombin-activatable fibrinolysis inhibitor in hypothyroidism and hyperthyroxinaemia
    Verkleij, Chantal J. N.
    Stuijver, Danka J. F.
    van Zaane, Bregje
    Squizzato, Alessandro
    Brandjes, Dees P. M.
    Buller, Harry R.
    Meijers, Joost C. M.
    Gerdes, Victor E. A.
    THROMBOSIS AND HAEMOSTASIS, 2013, 109 (02) : 214 - 220
  • [9] The effects of hyperglycaemia on thrombin-activatable fibrinolysis inhibitor
    Verkleij, Chantal J. N.
    Nieuwdorp, Max
    Gerdes, Victor E. A.
    Morgelin, Matthias
    Meijers, Joost C. M.
    Marx, Pauline F.
    THROMBOSIS AND HAEMOSTASIS, 2009, 102 (03) : 460 - 468
  • [10] Thrombin activatable fibrinolysis inhibitor: Not just an inhibitor of fibrinolysis
    Bajzar, L
    Jain, N
    Wang, P
    Walker, JB
    CRITICAL CARE MEDICINE, 2004, 32 (05) : S320 - S324
12345